Loading
Depressive Symptoms / Ketamine / Epilepsy · Phase 2 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 mechanistic study not yet recruiting, designed to identify electrophysiologic biomarkers of ketamine antidepressant response in adults with epilepsy undergoing intracranial electrode monitoring. No results are posted in this registry record; the study measures changes in prefrontal-posterior connectivity and cortical excitability as surrogate endpoints before and 24 hours after a single subanesthetic ketamine infusion.
Phase 2, Interventional, Single Group, Open label, Basic Science purpose. Epilepsy, Depressive Symptoms; age from 18 Years. Intervention: Intravenous Ketamine During sEEG Monitoring. n = 37. 1 site: United States.
This is a registered Phase 2 mechanistic study not yet recruiting, designed to identify electrophysiologic biomarkers of ketamine antidepressant response in adults with epilepsy undergoing intracranial electrode monitoring. No results are posted in this registry record; the study measures changes in prefrontal-posterior connectivity and cortical excitability as surrogate endpoints before and 24 hours after a single subanesthetic ketamine infusion.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mechanistic study cannot yet inform clinical practice, as results are not reported. Upon completion, electrophysiologic biomarkers identified may advance understanding of ketamine's antidepressant mechanism in this population, but the narrow epilepsy-with-intracranial-monitoring cohort limits generalizability to mainstream depression treatment.
Phase 2 mechanistic study in a highly selected population (epilepsy patients with intracranial electrodes) examining electrophysiologic biomarkers of ketamine response; no results yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This mechanistic study cannot yet inform clinical practice, as results are not reported. Upon completion, electrophysiologic biomarkers identified may advance understanding of ketamine's antidepressant mechanism in this population, but the narrow epilepsy-with-intracranial-monitoring cohort limits generalizability to mainstream depression treatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07768618). This is a study registration, not published results. Lead sponsor: Emory University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 37 participants (ESTIMATED). Conditions: Epilepsy, Depressive Symptoms. Interventions: DRUG: Ketamine. Primary outcome measures: Change in Prefrontal-Posterior Brain Connectivity , Baseline and approximately 24 hours post-ketamine infusion; Change in Prefrontal Cortical Excitability Measure , Baseline (pre-infusion) and approximately 24 hours post-ketamine infusion.. Brief summary: This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms. Participants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg/kg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.